ACP 319

Drug Profile

ACP 319

Alternative Names: ACP 319

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acerta Pharma
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B cell lymphoma
  • Phase I Chronic lymphocytic leukaemia

Most Recent Events

  • 31 Mar 2017 ACP 319 is still in phase I trials for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO)
  • 31 Mar 2017 ACP 319 is still in phase I/II trials for B-cell malignancies (Combination therapy) in USA (PO)
  • 01 Dec 2014 Phase-I/II clinical trials in B-cell lymphoma (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top